FDA Slaps ImmunityBio with Warning Letter Over Misleading ANKTIVA Ads
ImmunityBio shares dropped 20% after the FDA issued a warning letter accusing the company of false claims that ANKTIVA cures all cancers.
NOTRELOAD AI
Goldman Sachs Downgrades Ultragenyx to Neutral After Setrusumab Trial Miss
Goldman Sachs downgraded Ultragenyx from Buy to Neutral and slashed its price target to $25 after setrusumab Phase 3 miss in osteogenesis imperfecta. GTX-102 in Angelman syndrome now key focus, but risks remain.
FCC Bans New Foreign-Made Wi-Fi Routers Over Security Risks
The FCC has banned imports of all new foreign-produced Wi-Fi routers citing national security threats. What it means for TP-Link, Netgear, your home Wi-Fi and future router purchases.
Costco Challenges Celsius with New Kirkland Energy Drink
Costco’s new Kirkland Signature Sparkling Energy Drink closely mimics Celsius, with similar can size, caffeine content, and flavors. Stifel notes that this caused CELH stock to drop but sees only a near-term risk and maintains a Buy rating.
Half the Patients Saw Dramatic Spleen Shrinkage: SENTRY Trial Shows Strong Results (With One Notable Miss) for New Myelofibrosis Combo
Karyopharm’s (KPTI) SENTRY trial delivers strong spleen reduction and promising survival data with selinexor + ruxolitinib — though symptom improvement was not superior. $30M cash boost extends runway into late 2026.
“Huge Opportunity”: BofA Starts Coverage on Nebius with Buy Rating
Bank of America initiates coverage on Nebius with a Buy rating and $150 price target, implying 31% upside.